Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia
Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia
复制标题
DOI：
10.1038/sj.bmt.1705011
复制
发表时间：
2005-07-01
影响因子：
4.8
通讯作者：
De Lima, M
中科院分区：
文献类型：
--
作者：
Hosing, C;Saliba, RM;De Lima, M
异基因造血干细胞移植（HSCT）治疗急性髓性白血病（AML）失败的主要原因是疾病复发或进展。我们分析了在我们机构接受第二次HSCT治疗复发性难治性AML/骨髓增生异常综合征（MDS）患者的结局。共有72例患者符合本分析的条件。总共有25例（35%）患者在第二次移植手术前接受了补救化疗，只有2例（3%）患者在第二次移植时完全缓解。共有20例患者（28%）的白血病负荷较低，通过外周血原始细胞的缺乏来衡量，
The major cause of failure after allogeneic hematopoietic stem cell transplantation (HSCT) for acute myelogenous leukemia (AML) is disease relapse or progression. We analyzed the outcome of second HSCT for treatment of patients with relapsed, refractory AML/myelodysplastic syndrome (MDS) at our institution. A total of 72 patients were eligible for this analysis. In all, 25 (35%) patients received salvage chemotherapy prior to the second transplant procedure and only two (3%) patients were in complete remission at the time of the second transplant. A total of 20 patients (28%) had low leukemia burden as measured by the absence of peripheral blood blasts and